Insulet

  • Revenue$1.1 BFY, 2021
  • Market Capitalization$16.9 B2022-08-01

OverviewSuggest Edit

Insulet Corporation, a medical device company, develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The Company offers Omnipod Insulin Management System (Omnipod System), which consists of the OmniPod, an easy-to-use continuous insulin delivery system and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of subcutaneous drugs across various therapeutic areas. Insulet Corporation sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors.

TypePublic
Founded2000
HQActon, MA, USMap
Websiteinsulet.com
Employee Ratings3.6
Overall CultureC-More
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)1,350(+16%)
Revenue (FY, 2021)$1.1 B(+22%)
Share Price (Aug 2022)$245.7
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Insulet

Shacey Petrovic

Shacey Petrovic

Director, President, Chief Executive Officer
Charles Alpuche

Charles Alpuche

Executive Vice President, Chief Operating Officer
Jim Hollingshead

Jim Hollingshead

Director
Bret Christensen

Bret Christensen

Chief Commercial Officer
David A. Lemoine

David A. Lemoine

Director
Luciana Borio

Luciana Borio

Director
Show more

Insulet Office Locations

Insulet has offices in Acton, Billerica, Salt Lake City, San Diego and in 2 other locations
Acton, MA, US (HQ)
100 Nagog Park
Billerica, MA, US
600 Technology Park Dr
Salt Lake City, UT, US
155 N 400 W #300
San Diego, CA, US
9276 Scranton Rd #4
Oakville, CA
1540 Cornwall Rd
London, GB
5th, 1 King St
Show all (6)

Insulet Financials and Metrics

Insulet Revenue

Insulet's revenue was reported to be $1.1 b in FY, 2021
USD

Revenue (Q1, 2022)

295.4m

Gross profit (Q1, 2022)

209.7m

Net income (Q1, 2022)

27.8m

EBIT (Q1, 2022)

37.9m

Market capitalization (1-Aug-2022)

16.9b

Closing stock price (1-Aug-2022)

245.7

Cash (31-Mar-2022)

724.9m
Insulet's current market capitalization is $16.9 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Revenue

152.3m211.4m247.1m288.7m324.2m367.0m463.8m563.8m738.2m904.4m1.1b

Revenue growth, %

17%12%13%

Cost of goods sold

85.5m119.0m134.7m145.4m176.1m155.9m186.6m193.7m257.9m322.1m346.7m

Gross profit

66.7m92.3m112.4m143.3m148.2m211.1m277.2m370.2m480.3m582.3m752.1m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Revenue

32.2m44.6m47.8m51.0m54.8m57.4m60.1m61.1m69.2m72.0m75.0m61.2m75.6m87.3m81.2m87.3m94.9m101.7m109.8m121.8m123.6m124.3m151.1m159.6m177.1m192.1m1.5m226.3m500.0k252.3m263.2m275.6m295.4m

Cost of goods sold

17.7m26.0m27.5m28.7m30.4m32.2m33.3m33.7m36.4m36.2m36.9m28.4m41.2m51.7m37.2m36.9m39.2m42.3m45.1m48.2m47.8m42.2m49.1m52.9m60.7m69.0m71.1m83.8m82.2m84.8m80.5m86.9m85.7m

Gross profit

14.5m18.6m20.3m22.3m24.4m25.2m26.8m27.4m32.8m35.8m38.0m32.8m34.4m35.7m44.1m50.5m55.6m59.4m64.6m73.6m75.8m82.1m102.0m106.7m116.4m123.1m(69.6m)142.5m(81.7m)167.5m182.7m188.7m209.7m

Gross profit Margin, %

45%42%43%44%45%44%45%45%47%50%51%54%45%41%54%58%59%58%59%60%61%66%67%67%66%64%(4640%)63%(16340%)66%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Cash

94.0m57.3m149.7m151.2m122.7m137.2m272.6m113.9m213.7m907.2m806.4m

Accounts Receivable

23.2m33.3m33.1m39.9m48.4m28.8m53.4m63.3m69.3m83.8m

Prepaid Expenses

3.7m4.5m5.9m4.0m5.7m9.9m24.3m31.1m

Inventories

11.8m14.9m9.5m13.1m14.0m35.5m33.8m71.4m154.3m303.2m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Cash

106.7m103.8m83.0m70.1m63.4m148.1m150.9m153.9m145.6m175.5m146.4m145.6m145.1m145.5m111.6m75.7m215.4m76.0m73.5m102.2m203.1m136.2m126.6m129.3m119.9m419.9m201.4m779.1m838.1m820.7m854.6m856.6m724.9m

Accounts Receivable

20.4m17.3m26.2m25.6m30.1m31.1m33.7m34.5m36.7m41.8m47.1m36.1m31.8m31.8m40.5m38.7m38.5m40.6m37.8m47.2m50.4m49.7m70.0m68.7m67.0m65.1m80.1m85.4m97.9m100.3m114.3m153.5m

Prepaid Expenses

4.8m3.7m3.5m4.3m5.6m6.4m6.6m5.9m7.1m5.7m3.4m3.7m3.4m4.0m5.7m6.8m7.9m8.2m8.4m8.0m17.4m17.6m17.9m28.0m25.2m20.7m43.9m59.6m53.4m73.6m82.7m76.5m71.7m

Inventories

16.0m13.1m14.7m16.4m15.1m9.2m6.0m5.4m10.4m8.8m9.7m20.1m23.4m13.0m14.0m24.5m32.7m34.3m34.0m35.1m26.3m40.8m58.1m73.8m85.1m90.2m95.7m103.7m124.9m170.1m197.8m314.8m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Net Income

(45.8m)(51.9m)(45.0m)(51.5m)(73.5m)(28.9m)(26.8m)3.3m11.6m6.8m16.8m

Depreciation and Amortization

8.5m11.0m11.8m12.2m15.8m13.8m15.1m15.6m27.9m55.4m64.2m

Inventories

1.9m(3.0m)5.4m(3.6m)(722.0k)(24.1m)1.7m(38.8m)(30.2m)(50.5m)(154.4m)

Accounts Payable

7.1m(15.6m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Net Income

(29.3m)(42.8m)(14.8m)(29.3m)(41.7m)(10.7m)(21.2m)(42.5m)(6.1m)(35.3m)(46.1m)(11.8m)(27.3m)(46.2m)(12.5m)(16.7m)(19.8m)(10.0m)(17.7m)(20.0m)(6.6m)(8.3m)(6.6m)4.4m5.8m6.6m(2.1m)12.3m23.9m(12.4m)27.8m

Depreciation and Amortization

2.8m5.7m2.8m5.5m8.1m2.9m5.8m8.9m3.1m6.1m9.2m3.4m7.1m11.4m3.4m6.8m10.5m3.3m6.7m10.5m3.5m7.9m11.3m5.1m11.0m18.8m9.7m18.8m29.7m12.8m3.5m42.5m15.3m

Inventories

(2.2m)594.0k(2.9m)(4.6m)(3.3m)5.7m8.9m9.5m(985.0k)699.0k(198.0k)(7.0m)(10.3m)312.0k(2.6m)(13.1m)(21.3m)1.2m1.5m428.0k6.7m(8.0m)(25.3m)(2.7m)(14.0m)(20.0m)4.8m(2.8m)(22.9m)(17.9m)(108.1m)

Accounts Payable

2.2m1.9m(4.4m)14.7m
show all
USDQ2, 2011

Financial Leverage

2.4 x
Show all financial metrics

Insulet Operating Metrics

FY, 2016

Patents Issued

23

Patents Pending

32

Insulet Revenue Breakdown

Embed Graph

Insulet revenue breakdown by business segment: 62.6% from U.S. Omnipod, 19.6% from International Omnipod and 17.8% from Drug Delivery

Insulet Cybersecurity Score

Cybersecurity ratingPremium dataset

C

77/100

Learn more about our premium products
SecurityScorecard logo

Insulet Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Insulet Online and Social Media Presence

Insulet's Trends

Embed Graph

Insulet Company Culture

  • Overall Culture

    C-

    63/100

  • CEO Rating

    C

    65/100

  • Compensation

    C+

    66/100

  • Diversity

    C-

    64/100

Learn more on Comparably

Insulet News and Updates

June 27, 2022

Insights on the Ultra large Volume Wearable Injectors Global Market to 2027 - Featuring Amgen, BASF and Insulet Among Others

Dublin, June 27, 2022 (GLOBE NEWSWIRE) -- The "Global Ultra large Volume Wearable Injectors Market (2022-2027) by Product, Application, Geography, Competitive Analysis, and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering. The Global Ultra lar…
April 01, 2022

What Makes Insulet Stock A Good Bet?

We think that Insulet stock, a company best known for selling the Omnipod continuous insulin delivery system that caters to people with diabetes, currently is a better pick compared to ConMed (NASDAQ: CNMD), a medical devices company that specializes in products for orthopedic and general surgery..
March 14, 2022

Global Insulin Patch Pumps Market Report 2022-2029 Featuring Insulet, J&J, Medtrum Technologies, Roche, Cellnovo, Spring Health Solution, Debiotech, CeQur, Valeritas, BD & Co

Dublin, March 14, 2022 (GLOBE NEWSWIRE) -- The "Insulin Patch Pumps Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering. Diabetes is a chronic d…
February 09, 2022

Global Connected Medical Devices Market Growth Opportunities Report 2021 Featuring Adherium, AliveCor, Beddr Sleep, Cognita Labs, Insulet, & OnDosis

Dublin, Feb. 09, 2022 (GLOBE NEWSWIRE) -- The "Global Connected Medical Devices Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
October 22, 2021

Global Drug Delivery Devices Market Report 2021-2026 Featuring 3M, AstraZeneca, BD & Co, Boehringer Ingelheim, GSK, Insulet, Medtronic, Sulzer and West Pharmaceuticals Services

DUBLIN, Oct. 22, 2021 /PRNewswire/ -- The "Global Drug Delivery Devices Market (2021-2026) by device type, route of administration, application, end-user, vehicle outlook, Geography, Competitive Analysis and the Impact of COVID-19 with Ansoff Analysis" report has been added to...
July 16, 2021

Worldwide Artificial Pancreas Device Systems Industry to 2026 - Key Players Include Beta Bionics, Dexcom and Insulet Among Others

Dublin, July 16, 2021 (GLOBE NEWSWIRE) -- The "Artificial Pancreas Device Systems (APDS) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The global artificial pancreas device systems (APDS) market …
Show more

 Insulet Frequently Asked Questions

  • When was Insulet founded?

    Insulet was founded in 2000.

  • Who are Insulet key executives?

    Insulet's key executives are Shacey Petrovic, Charles Alpuche and Jim Hollingshead.

  • How many employees does Insulet have?

    Insulet has 1,350 employees.

  • What is Insulet revenue?

    Latest Insulet annual revenue is $1.1 b.

  • What is Insulet revenue per employee?

    Latest Insulet revenue per employee is $813.9 k.

  • Who are Insulet competitors?

    Competitors of Insulet include Tandem Diabetes Care, Reapplix and POPS! Diabetes Care.

  • Where is Insulet headquarters?

    Insulet headquarters is located at 100 Nagog Park, Acton.

  • Where are Insulet offices?

    Insulet has offices in Acton, Billerica, Salt Lake City, San Diego and in 2 other locations.

  • How many offices does Insulet have?

    Insulet has 6 offices.